{ }
BNB Chain experienced a significant rise in sandwich attacks, with 35% of November transactions affected, leading investors to seek alternatives like Uniswap, which saw a 70% increase in price. Meanwhile, Rollblock's crypto presale has gained traction, boasting a 310% return and potential for 100x growth ahead of its ICO in early 2025.
Bitcoin remains steady above $100,000, with traders anticipating a significant price movement as CME Options Open Interest data indicates increased institutional activity. The cryptocurrency is testing key resistance at $103,600; a breakthrough could lead to new highs, while failure may trigger a correction towards $95,500. Market participants are on alert for potential volatility in the coming days.
Hedge funds have set a record for short positions against Ethereum on the CME, reaching 6,349 contracts, despite over $2 billion in inflows into Ethereum ETFs. This cautious outlook contrasts with long-term optimism, as analysts note Ethereum's realized price upper band at $5,200, indicating potential for growth. Network activity remains strong, with over 130,000 new addresses created daily and weekly transaction fees hitting $67 million, driven by robust DeFi engagement.
Institutional funds are increasingly flowing into Ethereum, with a recent net inflow of $831 million over a week, pushing its price to around $3,900. Analysts predict that if this trend continues, Ethereum could surpass its all-time high of $4,868 and reach $7,000 next year, bolstered by significant purchases from asset management firms and the World Liberty Financial project.
CRISPR Therapeutics' CEO sold shares at an average price of $46.28, totaling $198,680.04, reducing their ownership by 1.86%. General Counsel James R. Kasinger also sold shares, resulting in a 1.71% decrease in their holdings. Insiders have sold 50,382 shares valued at $2,744,179 in the last three months, with 4.10% of the stock owned by insiders. The company reported a quarterly loss of $1.01 EPS, exceeding estimates, while analysts maintain a "Hold" rating with a consensus target price of $77.93.
Chainlink's price has surged to a two-year high, accompanied by a record-breaking open interest of $770 million in its futures market, surpassing competitors like TON and TRX. This increase reflects heightened market activity and confidence, with $35.57 million in realized profits indicating significant short-term trading. Despite improved active address momentum, user engagement remains well below 2021 peaks, suggesting that current price dynamics are largely driven by speculative trading rather than sustainable growth.
Larson Financial Group LLC and GPS Wealth Strategies Group LLC significantly increased their stakes in CRISPR Therapeutics during the second quarter, with institutional investors now owning 69.20% of the company. The stock recently hit a 52-week low of $43.23, and analysts have mixed ratings, with a consensus "Hold" and an average target price of $77.93. In its latest earnings report, CRISPR posted a loss of $1.01 per share, beating estimates but falling short on revenue expectations.
Two research analysts have rated Novartis AG stock as a sell, while seven have issued a hold rating, resulting in an average rating of "Hold" and a target price of $121.50. Recently, Sanctuary Advisors LLC increased its stake in Novartis by 14.9%, with other hedge funds also boosting their positions. The company reported earnings of $2.06 per share, exceeding estimates, and has a market cap of $201.13 billion.
Tech leaders, including Jeff Bezos of Amazon, Mark Zuckerberg of Meta, and Sundar Pichai of Alphabet, are actively engaging with Donald Trump to navigate potential challenges posed by his administration. Bezos praised Trump's newfound calmness, while Zuckerberg reflected on his own reactions to recent events, and Pichai expressed optimism about future innovations under Trump's leadership.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.